Hospital
Fisher-Titus Medical Center
Fisher-Titus Medical Center was paid $23.40M by Medicaid between Jan 2018 and Dec 2024, across 303 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 15% of everything it billed.
33Billing provider infoFISHER-TITUS MEDICAL CENTER
NORWALK, OH 44857
NORWALK, OH 44857
33aNPI1992738959assigned 07/09/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.40M
24GClaims634,427
24DCodes billed303
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#49 of 101
Median peer was paid$22.32M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 64,138 | $1.73M | |
| 2019 | 56,916 | $1.52M | |
| 2020 | 39,953 | $1.40M | |
| 2021 | 58,816 | $2.61M | |
| 2022 | 70,359 | $3.60M | |
| 2023 | 198,601 | $7.39M | |
| 2024incomplete | 145,644 | $5.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 40,356 | 34,238 | $3.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 31,624 | 28,610 | $3.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 23,798 | 20,926 | $2.70M |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 9,044 | 7,380 | $2.53M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.4% | 19,764 | 17,339 | $1.95M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.3% | 13,157 | 10,672 | $1.46M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.1% | 10,726 | 3,710 | $728K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 2,122 | 1,748 | $540K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 4,794 | 4,378 | $399K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 2,141 | 1,788 | $387K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.6% | 8,603 | 2,111 | $385K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.6% | 1,257 | 1,081 | $375K |
291 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 4,552 | $320K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 2,607 | $292K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 922 | $237K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 919 | $185K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,637 | $156K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,643 | $156K |
| G0378 | Hospital observation service, per hour | <1% | 3,087 | $145K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,806 | $140K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,913 | $138K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 628 | $136K |
| 90837 | Psychotherapy session, about an hour | <1% | 1,155 | $133K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 430 | $107K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,912 | $106K |
| 80053 | Comprehensive metabolic panel | <1% | 9,265 | $104K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,611 | $104K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,410 | $93K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 573 | $89K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,039 | $83K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 372 | $75K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,003 | $74K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 680 | $71K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,107 | $70K |
| 97162 | <1% | 1,143 | $65K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,064 | $59K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 317 | $57K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 622 | $57K |
| 80061 | Lipid panel | <1% | 3,264 | $53K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 532 | $52K |
| 81003 | <1% | 3,380 | $52K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,428 | $51K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,025 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,105 | $48K |
| 36415 | Collection of venous blood by venipuncture | <1% | 41,276 | $45K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 655 | $44K |
| 86900 | <1% | 2,322 | $42K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 273 | $42K |
| 80076 | <1% | 13,254 | $41K | |
| 87400 | <1% | 4,742 | $39K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,016 | $38K |
| 84484 | <1% | 11,608 | $35K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,252 | $34K |
| 96113 | <1% | 154 | $33K | |
| 86592 | <1% | 1,533 | $33K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 121 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,209 | $28K |
| 86850 | <1% | 2,297 | $27K | |
| 86762 | <1% | 923 | $26K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 535 | $25K |
| 85027 | <1% | 2,714 | $24K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,777 | $23K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,452 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,257 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,298 | $22K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 169 | $21K |
| 97116 | <1% | 622 | $21K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,333 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,669 | $20K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 14 | $19K |
| 85018 | <1% | 1,636 | $19K | |
| 83655 | <1% | 1,122 | $18K | |
| 74018 | <1% | 826 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 949 | $17K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,621 | $16K |
| 87653 | <1% | 383 | $15K | |
| 92567 | <1% | 188 | $15K | |
| 80320 | <1% | 1,135 | $15K | |
| 86901 | <1% | 2,283 | $14K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 40 | $14K |
| 93017 | <1% | 196 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,552 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,649 | $13K |
| 87340 | <1% | 1,046 | $13K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 192 | $13K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 79 | $13K |
| 88342 | <1% | 1,190 | $12K | |
| 73564 | <1% | 763 | $11K | |
| 94726 | <1% | 159 | $11K | |
| 82607 | <1% | 1,186 | $11K | |
| 84466 | <1% | 869 | $11K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,774 | $11K |
| 81001 | <1% | 19,712 | $10K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $10K |
| 92552 | <1% | 211 | $10K | |
| 43235 | <1% | 31 | $10K | |
| 84702 | <1% | 695 | $9K | |
| 83605 | <1% | 2,594 | $9K | |
| 87506 | <1% | 60 | $9K | |
| 82728 | <1% | 1,160 | $9K | |
| 84439 | <1% | 977 | $9K | |
| 94729 | <1% | 123 | $8K | |
| 73630 | <1% | 765 | $8K | |
| 83540 | <1% | 1,080 | $8K | |
| 92526 | <1% | 102 | $7K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 52 | $7K |
| 0002A | <1% | 316 | $7K | |
| 76641 | <1% | 74 | $7K | |
| 72110 | <1% | 180 | $7K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 218 | $7K |
| 96112 | <1% | 154 | $6K | |
| 81002 | <1% | 255 | $6K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 218 | $6K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 678 | $6K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 270 | $6K |
| 80051 | <1% | 423 | $6K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $6K |
| 82553 | <1% | 487 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 530 | $5K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 44 | $5K |
| 87186 | <1% | 1,278 | $5K | |
| 73030 | <1% | 485 | $5K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,510 | $5K |
| 85730 | <1% | 8,784 | $5K | |
| 86140 | <1% | 1,198 | $5K | |
| 93971 | <1% | 68 | $5K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,763 | $5K |
| 83735 | <1% | 2,415 | $5K | |
| 73130 | <1% | 486 | $5K | |
| 92523 | <1% | 64 | $4K | |
| 82950 | <1% | 358 | $4K | |
| 0001A | <1% | 344 | $4K | |
| 97167 | <1% | 49 | $4K | |
| 73610 | <1% | 619 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 365 | $4K |
| 85652 | <1% | 1,071 | $4K | |
| 85610 | <1% | 9,185 | $4K | |
| 85014 | <1% | 668 | $4K | |
| 82805 | <1% | 101 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 172 | $4K |
| 86038 | <1% | 327 | $4K | |
| 96376 | <1% | 1,754 | $4K | |
| 82565 | <1% | 722 | $4K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $4K |
| 12001 | <1% | 18 | $4K | |
| 86769 | <1% | 74 | $3K | |
| 73502 | <1% | 233 | $3K | |
| 84436 | <1% | 484 | $3K | |
| 82784 | <1% | 339 | $3K | |
| 83874 | <1% | 495 | $3K | |
| 87420 | <1% | 682 | $3K | |
| 82746 | <1% | 595 | $3K | |
| 84403 | <1% | 164 | $3K | |
| 83690 | <1% | 10,849 | $3K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 20 | $3K |
| 84481 | <1% | 144 | $3K | |
| 97113 | <1% | 49 | $3K | |
| 71250 | <1% | 71 | $3K | |
| 94060 | <1% | 45 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 12 | $3K |
| 73110 | <1% | 371 | $3K | |
| 59025 | Fetal non-stress test | <1% | 43 | $3K |
| 87081 | <1% | 1,983 | $3K | |
| 90715 | <1% | 215 | $3K | |
| 87077 | <1% | 1,329 | $3K | |
| 84520 | <1% | 413 | $3K | |
| 91300 | <1% | 602 | $3K | |
| 17110 | <1% | 15 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,161 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 212 | $2K |
| 82947 | <1% | 458 | $2K | |
| 84156 | <1% | 318 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,119 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,680 | $2K |
| 83001 | <1% | 149 | $2K | |
| 87070 | <1% | 438 | $2K | |
| 82043 | <1% | 490 | $2K | |
| 76775 | <1% | 17 | $2K | |
| 90785 | <1% | 44 | $2K | |
| 82570 | <1% | 434 | $2K | |
| 81025 | <1% | 2,145 | $2K | |
| 83880 | <1% | 828 | $2K | |
| 00731 | <1% | 813 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 395 | $2K |
| 72100 | <1% | 170 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 12 | $2K |
| 80069 | <1% | 55 | $2K | |
| 87040 | <1% | 1,075 | $2K | |
| 83525 | <1% | 115 | $2K | |
| 91200 | <1% | 13 | $1K | |
| 97035 | <1% | 152 | $1K | |
| J3490 | Unclassified drugs | <1% | 922 | $1K |
| 83002 | <1% | 81 | $1K | |
| 84703 | <1% | 2,295 | $1K | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $1K |
| 86364 | <1% | 54 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 30 | $1K |
| 84153 | <1% | 109 | $1K | |
| 99406 | <1% | 81 | $1K | |
| 80305 | <1% | 53 | $1K | |
| 97032 | <1% | 162 | $982.08 | |
| 83037 | <1% | 185 | $964.12 | |
| 93226 | <1% | 14 | $943.79 | |
| 51798 | <1% | 576 | $898.48 | |
| 97161 | <1% | 14 | $891.81 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $806.28 |
| 88141 | <1% | 60 | $747.48 | |
| G0008 | Administration of influenza virus vaccine | <1% | 162 | $717.95 |
| 90686 | <1% | 107 | $716.61 | |
| 84480 | <1% | 30 | $604.62 | |
| 97166 | <1% | 15 | $599.17 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 757 | $564.22 |
| 87205 | <1% | 106 | $561.94 | |
| 96367 | <1% | 40 | $519.28 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 289 | $517.16 |
| 73080 | <1% | 72 | $464.85 | |
| 82533 | <1% | 24 | $454.56 | |
| 93225 | <1% | 14 | $450.69 | |
| 84402 | <1% | 21 | $441.53 | |
| 80074 | <1% | 29 | $439.86 | |
| 83630 | <1% | 28 | $431.78 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,507 | $402.08 |
| 84550 | <1% | 50 | $400.72 | |
| 70486 | <1% | 27 | $389.69 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,314 | $329.89 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 356 | $308.82 |
| 97165 | <1% | 15 | $297.28 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 181 | $291.52 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 924 | $278.45 |
| 87329 | <1% | 13 | $272.51 | |
| 76801 | <1% | 13 | $266.30 | |
| 86308 | <1% | 72 | $246.97 | |
| 82550 | <1% | 593 | $243.62 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 478 | $225.33 |
| 86431 | <1% | 14 | $224.58 | |
| 87209 | <1% | 13 | $193.80 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,007 | $190.21 |
| 86803 | <1% | 16 | $184.26 | |
| 84132 | <1% | 121 | $168.52 | |
| 00813 | <1% | 266 | $166.69 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 931 | $162.65 |
| 87177 | <1% | 13 | $161.26 | |
| 82248 | <1% | 20 | $158.89 | |
| 87075 | <1% | 41 | $157.42 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 547 | $138.91 |
| 85007 | <1% | 91 | $132.46 | |
| 73140 | <1% | 13 | $132.26 | |
| 94760 | <1% | 1,258 | $130.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 519 | $124.53 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,001 | $124.47 |
| 85379 | <1% | 368 | $123.43 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,210 | $96.00 |
| 80329 | <1% | 117 | $87.37 | |
| 84100 | <1% | 15 | $86.80 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 518 | $77.65 |
| 88304 | <1% | 36 | $74.99 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,171 | $68.01 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 500 | $65.24 |
| 73590 | <1% | 28 | $64.20 | |
| 51702 | <1% | 17 | $60.68 | |
| A9270 | Non-covered item or service | <1% | 4,603 | $57.08 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 430 | $55.63 |
| 90656 | <1% | 26 | $54.20 | |
| 83615 | <1% | 13 | $53.12 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 146 | $47.65 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,664 | $37.86 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 882 | $37.69 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 67 | $37.50 |
| 84295 | <1% | 31 | $35.76 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,532 | $34.34 |
| 82330 | <1% | 34 | $29.40 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 234 | $29.24 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,208 | $23.65 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 291 | $22.77 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 149 | $18.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 641 | $14.81 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 210 | $14.30 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 111 | $12.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 706 | $4.78 |
| 69209 | <1% | 19 | $4.20 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 40 | $3.87 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 211 | $1.97 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 134 | $1.00 |
| J1815 | Injection, insulin, per 5 units | <1% | 24 | $0.93 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 18 | $0.93 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 923 | $0.87 |
| 91307 | <1% | 20 | $0.16 | |
| 82150 | 0% | 19 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 53 | $0.00 |
| 94761 | 0% | 83 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 29 | $0.00 |
| C1769 | Guide wire | 0% | 49 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 19 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 90 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 42 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| 00126 | 0% | 14 | $0.00 | |
| 00811 | 0% | 73 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 759 | $0.00 |
| 01992 | 0% | 212 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 127 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 52 | $0.00 |
| 36600 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARTIN, PATRICK (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Sirius Vision Optical INC | Burnsville, MN | $19K |
| Sirius Vision Optometry PC | Burnsville, MN | $341.78 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.